BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq:BCRX) will present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 8:45 a.m. ET. The event will be streamed live via the Investors section of BioCryst’s website, with a replay available afterward. BioCryst focuses on developing oral medications for rare diseases, with products like ORLADEYO™ approved in the U.S. and Japan for HAE attack prevention. The company also has ongoing programs for additional treatments, including BCX9930 and BCX9250, targeting various rare conditions.

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20^th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m. ET.

Links to a live audio webcast and replay of this presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Contact:
Investors
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com 

FAQ

When is BioCryst Pharmaceuticals presenting at the Needham Virtual Healthcare Conference?

BioCryst Pharmaceuticals will present on April 14, 2021, at 8:45 a.m. ET.

Where can I watch BioCryst Pharmaceuticals' presentation?

The presentation can be watched live and will be replayed in the Investors section of BioCryst's website.

What is BioCryst Pharmaceuticals focusing on in its development programs?

BioCryst is focused on developing treatments for rare diseases, including oral medications like ORLADEYO™ and other projects like BCX9930.

What is ORLADEYO™ and where is it approved?

ORLADEYO™ is an oral medication approved in the U.S. and Japan for preventing HAE attacks in patients aged 12 and older.

What are some other drug candidates BioCryst Pharmaceuticals is working on?

Other candidates include BCX9930 for complement-mediated diseases and BCX9250 for fibrodysplasia ossificans progressiva.